Jonathan Chambers1, Madhu Page-Sharp2, Sam Salman3, John Dyer1, Timothy M E Davis3, Kevin T Batty2, Laurens Manning4. 1. Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia. 2. School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Western Australia, Australia. 3. Faculty of Health and Medical Sciences, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia. 4. Faculty of Health and Medical Sciences, Harry Perkins Research Institute, Fiona Stanley Hospital, University of Western Australia, PO Box 404, Bull Creek 6149, Murdoch, Western Australia, Australia. laurens.manning@uwa.edu.au.
Abstract
PURPOSE: Ertapenem is used off-label to treat osteoarticular infections but there are few pharmacokinetic (PK) data to guide optimal dosing strategies in patients who may be obese with multiple co-morbidities including diabetes and peripheral vascular disease. METHODS: Participants undergoing lower limb amputation or elective joint arthroplasty received a dose of intravenous ertapenem prior to surgery. Eight plasma samples were collected over 24 h, together with at least one bone sample per patient. Ertapenem concentrations in plasma and bone were measured using liquid-chromatography/mass-spectroscopy and analysed using non-linear mixed effects PK modelling. RESULTS: Plasma and bone concentrations were obtained from 10 participants. The final population PK model showed that a fat free body mass was the most appropriate body size adjustment. Ertapenem diffused rapidly into bone but concentrations throughout the 24 h dosing period were on average 40-fold higher in plasma, corresponding to a bone to plasma ratio of 0.025, and highly variable between individuals. Simulations demonstrated a high probability of target attainment (PTA) for free plasma concentrations when the minimum inhibitory concentrations (MIC) were ≤ 0.25 mg/L. By contrast, at MICs of 0.5 mg/L and ≥ 1 mg/L, the fractions of patients attaining this target was ~ 80% and 40%, respectively. In bone, the PTA was ≤ 45% when the MIC was ≥ 0.25 mg/L. CONCLUSION: Local bone and free plasma concentrations appear adequate for osteoarticular infections where Enterobacteriaceae are the main causative pathogens, but for Staphylococcus aureus and other bacteria, conventional dosing may lead to inadequate PTA.
PURPOSE:Ertapenem is used off-label to treat osteoarticular infections but there are few pharmacokinetic (PK) data to guide optimal dosing strategies in patients who may be obese with multiple co-morbidities including diabetes and peripheral vascular disease. METHODS:Participants undergoing lower limb amputation or elective joint arthroplasty received a dose of intravenous ertapenem prior to surgery. Eight plasma samples were collected over 24 h, together with at least one bone sample per patient. Ertapenem concentrations in plasma and bone were measured using liquid-chromatography/mass-spectroscopy and analysed using non-linear mixed effects PK modelling. RESULTS: Plasma and bone concentrations were obtained from 10 participants. The final population PK model showed that a fat free body mass was the most appropriate body size adjustment. Ertapenem diffused rapidly into bone but concentrations throughout the 24 h dosing period were on average 40-fold higher in plasma, corresponding to a bone to plasma ratio of 0.025, and highly variable between individuals. Simulations demonstrated a high probability of target attainment (PTA) for free plasma concentrations when the minimum inhibitory concentrations (MIC) were ≤ 0.25 mg/L. By contrast, at MICs of 0.5 mg/L and ≥ 1 mg/L, the fractions of patients attaining this target was ~ 80% and 40%, respectively. In bone, the PTA was ≤ 45% when the MIC was ≥ 0.25 mg/L. CONCLUSION: Local bone and free plasma concentrations appear adequate for osteoarticular infections where Enterobacteriaceae are the main causative pathogens, but for Staphylococcus aureus and other bacteria, conventional dosing may lead to inadequate PTA.
Entities:
Keywords:
Antimicrobial bone concentrations; Bone to plasma ratio; Diabetic foot infection; Ertapenem; Osteoarticular infections; Osteomyelitis
Authors: Hanneke M J Nijland; Rovina Ruslami; Janneke E Stalenhoef; Erni J Nelwan; Bachti Alisjahbana; Ron H H Nelwan; Andre J A M van der Ven; Halim Danusantoso; Rob E Aarnoutse; Reinout van Crevel Journal: Clin Infect Dis Date: 2006-08-22 Impact factor: 9.079
Authors: Benjamin A Lipsky; David G Armstrong; Diane M Citron; Alan D Tice; David E Morgenstern; Murray A Abramson Journal: Lancet Date: 2005-11-12 Impact factor: 79.321
Authors: A K Majumdar; D G Musson; K L Birk; C J Kitchen; S Holland; J McCrea; G Mistry; M Hesney; L Xi; S X Li; R Haesen; R A Blum; R L Lins; H Greenberg; S Waldman; P Deutsch; J D Rogers Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191